American Century Companies Inc. Has $2.55 Million Stock Position in Astrana Health, Inc. (NASDAQ:ASTH)

American Century Companies Inc. reduced its holdings in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 14.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,837 shares of the company's stock after selling 13,703 shares during the period. American Century Companies Inc. owned approximately 0.14% of Astrana Health worth $2,549,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. State Street Corp acquired a new stake in Astrana Health in the 3rd quarter worth $91,966,000. Geode Capital Management LLC bought a new position in Astrana Health during the third quarter valued at about $58,995,000. Principal Financial Group Inc. acquired a new position in Astrana Health in the 3rd quarter valued at approximately $13,383,000. Royce & Associates LP lifted its position in shares of Astrana Health by 122.3% in the 4th quarter. Royce & Associates LP now owns 255,552 shares of the company's stock worth $8,058,000 after acquiring an additional 140,584 shares during the period. Finally, HighTower Advisors LLC acquired a new stake in shares of Astrana Health during the 3rd quarter worth approximately $5,799,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ASTH shares. Barclays started coverage on Astrana Health in a research note on Tuesday, April 1st. They issued an "equal weight" rating and a $36.00 target price for the company. Robert W. Baird reduced their price objective on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Macquarie raised shares of Astrana Health to a "hold" rating in a research note on Monday, December 16th. Stifel Nicolaus cut their price target on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Finally, Bank of America decreased their price objective on Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Astrana Health currently has an average rating of "Moderate Buy" and a consensus target price of $53.29.

Astrana Health Price Performance

ASTH traded up $0.88 during trading on Friday, hitting $33.10. The company's stock had a trading volume of 176,494 shares, compared to its average volume of 271,142. The firm's 50 day moving average price is $32.40 and its two-hundred day moving average price is $40.03. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 25.46, a price-to-earnings-growth ratio of 1.37 and a beta of 1.04. Astrana Health, Inc. has a 12 month low of $23.12 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). The company had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. Sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.